• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

May 化生性乳腺癌实际上是基底样癌吗?通过超微结构和生存分析的进一步证据研究。

May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis.

机构信息

Department of Pathology, Nanjing Jinling Hospital, 210002 Nanjing, Peoples Republic of China.

出版信息

Med Oncol. 2011 Mar;28(1):42-50. doi: 10.1007/s12032-009-9399-1. Epub 2009 Dec 30.

DOI:10.1007/s12032-009-9399-1
PMID:20041316
Abstract

Metaplastic breast carcinoma (MBC) encompasses a heterogeneous group of tumors. Based upon the microarray of MBCs, these tumors showed features of basal-like carcinoma and myoepithelial differentiation. However, MBCs entity still remained unclear. So we performed a systematic research to explicit metaplastic breast carcinomas further. A panel of ER, PR, HER-2, CK5/6, CK14, P63 and EGFR were prepared for detection of MBCs, and fluorescence in situ hybridization for HER-2 gene amplification and ultrastructure observation were also performed. Sensitiveness between CK5/6 and other antibodies in diagnosis was analysed, and survival analysis was also carried out. ER, PR and HER-2 were negative. CK5/6 (12/12), CK14 (9/12), EGFR (10/12) and P63 (8/12) were positive. FISH for HER-2 displayed no amplification (ratio values < 1.8). Ultrastructure showed tonofibrils, thin filament and dense body in the cytoplasm. Significant statistical differences were detected between groups (F = 8.080, P = 0.000) of score of CK5/6, CK14, P63 and EGFR. Significant statistical differences were also detected between age and lymph node involvement and survival (χ(2) = 10.835, P = 0.004). MBCs may be actually basal-like carcinomas. In the diagnosis of MBCs, CK5/6, CK14, P63 and EGFR may be effective and CK5/6 may be more sensitive than CK14 and P63. Survival of MBCs may be associated with age and lymph node involvement. However, given the limitations of our research accumulated cases, prospective clinicopathologic studies are needed to further elucidate MBCs.

摘要

化生性乳腺癌(MBC)包含一组异质性肿瘤。基于 MBC 的基因微阵列分析,这些肿瘤表现出基底样癌和肌上皮分化的特征。然而,MBC 的实体仍然不清楚。因此,我们进行了一项系统的研究,以进一步明确化生性乳腺癌。我们准备了一组 ER、PR、HER-2、CK5/6、CK14、P63 和 EGFR 用于检测 MBC,并进行了荧光原位杂交检测 HER-2 基因扩增和超微结构观察。分析了 CK5/6 和其他抗体在诊断中的敏感性,并且还进行了生存分析。ER、PR 和 HER-2 均为阴性。CK5/6(12/12)、CK14(9/12)、EGFR(10/12)和 P63(8/12)阳性。HER-2 的 FISH 显示无扩增(比值 < 1.8)。超微结构显示细胞质中有张力纤维、细纤维和致密体。CK5/6、CK14、P63 和 EGFR 的评分组之间的差异具有统计学意义(F = 8.080,P = 0.000)。年龄和淋巴结受累与生存之间的差异也具有统计学意义(χ(2) = 10.835,P = 0.004)。MBC 实际上可能是基底样癌。在 MBC 的诊断中,CK5/6、CK14、P63 和 EGFR 可能是有效的,并且 CK5/6 可能比 CK14 和 P63 更敏感。MBC 的生存可能与年龄和淋巴结受累有关。然而,鉴于我们研究积累的病例的局限性,需要进行前瞻性临床病理研究以进一步阐明 MBC。

相似文献

1
May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis.May 化生性乳腺癌实际上是基底样癌吗?通过超微结构和生存分析的进一步证据研究。
Med Oncol. 2011 Mar;28(1):42-50. doi: 10.1007/s12032-009-9399-1. Epub 2009 Dec 30.
2
Metaplastic breast carcinomas are basal-like tumours.化生性乳腺癌是基底样肿瘤。
Histopathology. 2006 Jul;49(1):10-21. doi: 10.1111/j.1365-2559.2006.02467.x.
3
Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases.乳腺富脂性癌 17 例临床病理分析。
Ann Diagn Pathol. 2011 Aug;15(4):225-32. doi: 10.1016/j.anndiagpath.2010.10.006. Epub 2011 Mar 10.
4
Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators.与浸润性导管癌相比,具有独特临床病理特征的化生性乳腺癌及不良预后指标。
World J Surg Oncol. 2013 Jun 6;11:129. doi: 10.1186/1477-7819-11-129.
5
Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer.乳腺髓样癌中雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)、细胞角蛋白5/6(CK 5/6)、p63和表皮生长因子受体(EGFR)抗原表达的免疫组织化学分析
Tumori. 2008 Nov-Dec;94(6):838-44. doi: 10.1177/030089160809400611.
6
Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.从三阴性乳腺癌和 35 岁以下女性的组织微阵列中,通过差异标记物表达推断乳腺癌的基底上皮表型。
Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.
7
Immunohistochemical study of metaplastic carcinoma and central acellular carcinoma of the breast: central acellular carcinoma is related to metaplastic carcinoma.乳腺化生性癌和中央无细胞癌的免疫组织化学研究:中央无细胞癌与化生性癌相关。
Med Mol Morphol. 2012 Dec;45(1):14-21. doi: 10.1007/s00795-010-0536-x. Epub 2012 Mar 20.
8
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.化生性乳腺癌的分子分析:通过非整倍体导致表皮生长因子受体(EGFR)拷贝数增加
Mol Cancer Ther. 2008 Apr;7(4):944-51. doi: 10.1158/1535-7163.MCT-07-0570.
9
Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.脆性组氨酸三联体蛋白、含WW结构域的氧化还原酶蛋白Wwox和激活蛋白2γ的表达水平与乳腺癌的基础表型相关。
Cancer. 2009 Feb 15;115(4):899-908. doi: 10.1002/cncr.24103.
10
[Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].[免疫组织化学在基底样乳腺癌预后评估中的作用]
Zhonghua Bing Li Xue Za Zhi. 2009 Jan;38(1):23-8.

引用本文的文献

1
Metaplastic breast cancer with chondrosarcomatous differentiation combined with concurrent bilateral breast cancer: A case report.伴有软骨肉瘤分化的化生性乳腺癌合并双侧乳腺癌:一例报告
World J Clin Cases. 2022 May 26;10(15):5064-5071. doi: 10.12998/wjcc.v10.i15.5064.
2
A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma.安罗替尼治疗晚期乳腺化生性癌1例报告
Onco Targets Ther. 2021 Aug 27;14:4599-4607. doi: 10.2147/OTT.S318645. eCollection 2021.
3
Metaplastic carcinoma of the breast: an immunohistochemical study.

本文引用的文献

1
[Diagnostic pitfalls in mammary pathology. Case 7. Spindle-cell carcinoma of the breast or metaplastic carcinoma].[乳腺病理学中的诊断陷阱。病例7。乳腺梭形细胞癌或化生性癌]
Ann Pathol. 2009 Jun;29(3):223-7. doi: 10.1016/j.annpat.2009.02.013. Epub 2009 Jun 13.
2
[Basal-like breast cancer: a review].[基底样乳腺癌:综述]
Ann Pathol. 2009 Jun;29(3):180-6. doi: 10.1016/j.annpat.2009.04.001. Epub 2009 Jun 12.
3
The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma.
乳腺化生性癌:免疫组织化学研究。
Diagn Pathol. 2014 Jul 16;9:139. doi: 10.1186/1746-1596-9-139.
大多数三阴性乳腺癌可能对应于基底样癌,但三阴性乳腺癌并不等同于基底样癌。
Med Mol Morphol. 2009 Jun;42(2):128-31. doi: 10.1007/s00795-008-0428-5. Epub 2009 Jun 18.
4
Basal-like breast carcinoma: from expression profiling to routine practice.基底样乳腺癌:从表达谱分析到临床实践
Arch Pathol Lab Med. 2009 Jun;133(6):860-8. doi: 10.5858/133.6.860.
5
[Basal-like carcinoma of the breast].[乳腺基底样癌]
Acta Med Port. 2008 Jul-Aug;21(4):373-8. Epub 2008 Oct 24.
6
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.抗表皮生长因子受体(EGFR)抗体西妥昔单抗与DNA交联剂顺铂在吉非替尼耐药的MDA-MB-468细胞中的生长及分子相互作用:三阴性/基底样乳腺癌治疗的新前景
Int J Oncol. 2008 Dec;33(6):1165-76.
7
An in vitro multistep carcinogenesis model for human cervical cancer.一种用于人类宫颈癌的体外多步骤致癌模型。
Cancer Res. 2008 Jul 15;68(14):5699-705. doi: 10.1158/0008-5472.CAN-07-6862.
8
Is 'basal-like' carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes.乳腺“基底样”癌是一种独特的临床病理实体吗?一项带有警示说明的批判性综述。
Pathobiology. 2008;75(2):119-31. doi: 10.1159/000123850. Epub 2008 Jun 10.
9
Basal-like breast cancer: a critical review.基底样乳腺癌:一项批判性综述。
J Clin Oncol. 2008 May 20;26(15):2568-81. doi: 10.1200/JCO.2007.13.1748.
10
Patho-biological aspects of basal-like breast cancer.基底样乳腺癌的病理生物学方面
Breast Cancer Res Treat. 2009 Feb;113(3):411-22. doi: 10.1007/s10549-008-9952-1. Epub 2008 Mar 9.